Showing results (31-40 of 268) with videos related to
Sort By:
Pageof 27
Frontiers in Oncology|March 29, 2021
The Crosstalk Between Tumor Cells and the Immune Microenvironment in Breast Cancer: Implications for ImmunotherapyVincenzo Salemme, Giorgia Centonze, Federica Cavallo, et al.Future Oncology (London, England)|November 8, 2012
Current treatment strategies with lenalidomide in multiple myeloma and future perspectivesAlessandra Larocca, Federica Cavallo, Roberto Mina, et al.Clinical Lymphoma & Myeloma|October 10, 2006
Response to bortezomib and activation of osteoblasts in multiple myelomaMaurizio Zangari, Shmuel Yaccoby, Federica Cavallo, et al.Expert Review of Vaccines|November 8, 2013
Preclinical vaccines against mammary carcinomaPier-Luigi Lollini, Federica Cavallo, Carla De Giovanni, et al.Neoplasia (New York, N.Y.)|December 3, 2008
Sca-1 identifies the tumor-initiating cells in mammary tumors of BALB-neuT transgenic miceCristina Grange, Stefania Lanzardo, Federica Cavallo, et al.Cancer Immunology, Immunotherapy : CII|January 15, 2004
Immunological inhibition of carcinogenesisMichela Spadaro, Stefania Lanzardo, Claudia Curcio, et al.Leukemia & Lymphoma|April 25, 2007
The treatment of the elderly multiple myeloma patientsFederica Cavallo, Maria Teresa Ambrosini, Cecilia Rus, et al.Cancer Immunology, Immunotherapy : CII|February 21, 2008
Oncoantigens as anti-tumor vaccination targets: the chance of a lucky strike?Raffaele Adolfo Calogero, Elena Quaglino, Silvia Saviozzi, et al.International Journal of Molecular Sciences|December 16, 2020
Toll-Like Receptor 2 at the Crossroad between Cancer Cells, the Immune System, and the MicrobiotaAntonino Di Lorenzo, Elisabetta Bolli, Lidia Tarone, et al.Cancer Immunology, Immunotherapy : CII|January 27, 2011
2011: the immune hallmarks of cancerFederica Cavallo, Carla De Giovanni, Patrizia Nanni, et al.Pageof 27